Interventional Oncology Market Insights By Size, Share, Growth, Trend, Revenues

1. MarketsandMarkets Presents Interventional Oncology Market worth $2.9 billion by 2026 https://www.marketsandmarkets.com/Market-Reports/interventional-oncology-market-203687164.html

2. The report "Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) - Global Forecast to 2026" The global interventional oncology market size is estimated to be USD 1.9 billion in 2020 and is projected to reach USD 2.9 billion by 2026, at a CAGR of 6.8%. The increasing prevalence of diseases and disorders, technological advancements, and increased funding and public-private investments are the key factors driving the growth of the interventional oncology market. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownload

3. Objectives of the Study: • Demand for embolization devices result in the segment occupying the high share of the interventional oncology market • Liver cancer estimated to be the growing market • Liver cancer accounted for the largest share of the interventional oncology market in 2020. Interventional oncology plays a crucial role in treating liver cancer, as removing the tumor with surgery may not leave the tissue healthy enough for effective liver functioning. Thus, primary liver tumors or liver tumors resulting from metastatic cancers can effectively be treated using interventional oncology procedures. Owing to this, more than half of all treatments for primary and metastatic liver cancer are conducted using interventional oncology. • Asia Pacific likely to emerge as the fastest-growing interventional oncology market, globally • Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalyst

4. This research report categorizes the interventional oncology market based on product, procedure, cancer type, end user, and region. • By Product • Embolization Devices • Ablation Devices • Support Devices • By Procedure • Thermal Tumor Ablation • Non-Thermal Tumor Ablation • Transcatheter Arterial Chemoembolization • Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy • Transcatheter Arterial Embolization/Bland Embolization • By Cancer Type • Liver Cancer • Lung Cancer • Bone Metastasis • Kidney Cancer • Breast Cancer • Prostate Cancer • Other Cancers

5. Medtronic, Boston Scientific, BD, Terumo, Merit Medical, AngioDynamics, J&J, Teleflex, Cook Medical, HealthTronics, MedWaves, Sanarus, IMBiotechnologies, Trod Medical, IceCure Medical, Mermaid Medicals, Interface Biomaterials BV, Guerbet, ABK Biomedical, Shape Memory Medical, Endo Shape, Monteris Medical, Instylla, Trisalus Lifesciences, Profound Medical Corp, Sirtex, Accuray, Baylis Medical, and ALPINION MEDICAL SYSTEMS and Among Others

6. Companies Insight Boston Scientific (US) dominated the global interventional oncology market in 2020. The company mainly focuses on growth strategies such as acquisitions and expansions to increase its market presence and product offerings. The company’s plan to acquire BTG will help expand its product offerings in chemoembolization, radioembolization, and ablation therapies. Boston Scientific constantly strives to gain regulatory and reimbursement approvals. As a part of its long-term growth strategy, the company invests in fast-growing markets as well as new markets by strengthening its position in the global healthcare market. Medtronic (Ireland) held the second position in the global interventional oncology market in 2020. The company focuses on adopting various organic growth strategies like product launches & approvals and inorganic growth strategies, such as acquisitions and collaborations, to expand its presence and share in the interventional oncology market. In line with this, the company launched various tumor management products like OptiSphere Embolization Spheres and OsteoCool Rf Ablation Systems and received US FDA clearance, which helped it to expand its presence in the market.

7. Contact Us Contact:Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee Road, Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 sales@marketsandmarkets.com Press release: https://www.marketsandmarkets.com/PressReleases/interventional-oncology.asp Research insights: https://www.marketsandmarkets.com/ResearchInsight/interventional-oncology-market.asp

8. About MarketsandMarkets MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.